Use of human MIR421 in preparation of preparations for diagnosing and treating prostate cancer

Abstract

The invention belongs to the biotechnical field, and concretely relates to a use of a new prostate cancer molecule marker microRNA 421 (MIR421) in the preparation of prostate cancer diagnosing and treating preparations and prostate cancer diagnosing kits. The use comprises the following steps: screening prostate cancer high-risk populations, diagnosing the prostate cancer, designing prostate cancer drug target, monitoring the prostate cancer treatment condition, and carrying out prognosis detection on the prostate cancer. A method using the molecule marker and a diagnostic kit containing the molecule marker to diagnose the prostate cancer has the characteristics of simplicity in operation, convenience in material drawing, good safety, no wounds, high specificity, high sensitivity, and easiness in massive screening.

Description

technical field [0001] The invention belongs to the field of biotechnology, and specifically relates to a new prostate cancer molecular marker MIR421 and its use in the preparation of diagnostic preparations for diagnosis and treatment of prostate cancer, including the screening of high-risk groups of prostate cancer through the biomolecular marker, Applications in the fields of diagnosis of prostate cancer, design of prostate cancer drug targets, monitoring of prostate cancer treatment status, monitoring of prostate cancer guiding medication, and detection of prostate cancer prognosis. Background technique [0002] According to relevant reports in the "ASCO Annual Report: 2015 Progress in Clinical Oncology", liquid biopsy technology is listed as one of the trends in the next ten years in the field of tumor treatment. Studies have shown that some molecular markers in the blood have been used in the diagnosis of some diseases, such as alanine aminotransferase for the diagnosi...

AI Technical Summary

Problems solved by technology

[0005] At present, the clinical diagnosis methods of prostate cancer mainly include digital rectal examination, serum prostate-specific antigen (PSA) detection, rectal ultrasound detection, biopsy pathological examination, etc. Among them, digital rectal examination is the simplest, most economical and practical method. Touching the prostate with the doctor's index finger is used to find many asymptomatic prostate cancer patients, and it is possible to obtain early diagnosis and radical treatment, but the above methods have limitations; for example, the limitations of digital rectal examination mainly lie in the following four aspects : (1) When the prostate tumor is not large, it is easy to miss the diagnosis; (2) Some patients have no obvious prostate cancer, but it is in the advanced stage, and it is not easy to cure; (3) This test cannot be used when the patient has rectal disease; (4) Inexperienced doctors may miss or misdiagnose

Under normal circumstances, the PSA in the blood is not high (not higher than 4 ng / ml). When in the state of prostate cancer and other prostate diseases, elevated PSA has become the most sensitive tumor marker for screening prostate cancer, but it is also There are certain limitations: (1) Blood testing is required, which will cause certain damage to the patient; (2) Elevated PSA is also common with non-prostate cancer diseases, such as prostatitis, prostatic hypertrophy, etc., so it is not easy to diagnose; (3) Elevated PSA When prostate cancer is diagnosed, the patients are often in the middle and late stage, and the purpose of early diagnosis cannot be achieved

Ultrasonic detection of the prostate is simple, intuitive, and non-invasive. It provides positioning by displaying the size, number, location, density, edge, shape, presence or absence of calcification, and the shape, size, number, and distribution of calcification, as well as surrounding halos and skin changes. and qualitative signs and judge the nature of the lesion; its limitations are: (1) it is easy to miss the diagnosis of dense small cancer focus; (2) sometimes it cannot provide a clear qualitative diagnosis; (3) because it cannot show the internal structure of the tumor (4) There is a high misdiagnosis rate for some solid benign and malignant masses lacking typical signs

Images